Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial) (PACE-RBBB)

Heart failure (HF) affects 5 million Americans and is responsible for more health-care expenditure than any other medical diagnosis. Approximately half of all HF patients have electrocardiographic prolongation of the QRS interval and ventricular dyssynchrony, a perturbation of the normal pattern of ventricular contraction that reduces the efficiency of ventricular work. Ventricular dyssynchrony is directly responsible for worsening HF symptomatology in this subset of patients. Resynchronization of ventricular contraction is usually achieved through simultaneous pacing of the left and right ventricles using a biventricular (BiV) pacemaker or implantable cardioverter-defibrillator. Clinical trial evidence supporting the use of BiV pacing in patients with prolonged QRS duration was obtained almost exclusively in patients with a left bundle-branch block (LBBB) electrocardiographic pattern. Recent evidence suggests that resynchronization of ventricular contraction in patients with LBBB can be obtained by univentricular left ventricular pacing with equal or superior clinical benefits compared to BiV pacing. Animal studies suggest that ventricular resynchronization can be obtained in subjects with right bundle-branch block (RBBB) through univentricular right ventricular pacing. No clinical trial evidence exists to support the use of BiV pacing in patients with RBBB. Thousands of patients with symptomatic HF and RBBB currently have univentricular ICDs in place for the prevention of sudden cardiac death. Most of these devices are currently programmed to avoid RV pacing. We aim to determine if ventricular resynchronization delivered through univentricular RV pacing improves symptoms in patients with RBBB and moderate to severe HF who have previously undergone BiV ICD implantation for symptomatic heart failure. We further aim to determine if ventricular resynchronization improves myocardial performance and ventricular geometry as detected by echocardiographic measures and quality of life for patients with HF and RBBB. We hypothesize that RV univentricular pacing delivered with an atrio-ventricular interval that maximizes ventricular synchrony is equivalent to BiV pacing for improvement in cardiac performance, HF symptoms, and positive ventricular remodeling in patients with HF and RBBB.

Study Overview

• Status: Terminated
• Conditions: Heart Failure; Right Bundle-Branch Block
• Intervention / Treatment: Device: VVI-40; Device: RV DDD-40; Device: BiV DDD-40

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Duke University Medical Center
    • Durham, North Carolina, United States, 27710
      • Durham VA Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Cardiomyopathy of either idiopathic or ischemic etiology
• NYHA class III, or IV symptoms
• Sinus rhythm
• QRS complex duration > 130 msec in ≥ 2 surface ECG leads with RBBB
• PR interval > 150 msec and < 240 msec
• Prior implantation of dual chamber BiV ICD with apical RV lead location

Exclusion Criteria:

• Myocardial infarction, major surgical procedure, or acute cardiac failure crisis requiring inotropes within 6 months of entry into the study
• Atrial fibrillation or flutter lasting >12 hours within the last 6 months
• Sick sinus syndrome, complete heart block, or other arrhythmias requiring pacemaker support
• Pregnancy
• Any other known condition other than heart failure that could limit exercise time or survival to < 6 months

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Triple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: VVI-40 to RV DDD-40 to Bi-V DDD-40; Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40	Device: VVI-40; Pacing mode set to VVI-40, RV only pacing; Device: RV DDD-40; ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.; Device: BiV DDD-40; ICD programmed to BiV pacing at a lower rate of 40
Experimental: VVI-40 to Bi-V DDD-40 to RV DDD-40; Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40	Device: VVI-40; Pacing mode set to VVI-40, RV only pacing; Device: RV DDD-40; ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.; Device: BiV DDD-40; ICD programmed to BiV pacing at a lower rate of 40
Experimental: Bi-V DDD-40 to VVI-40 to RV DDD-40; Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40	Device: VVI-40; Pacing mode set to VVI-40, RV only pacing; Device: RV DDD-40; ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.; Device: BiV DDD-40; ICD programmed to BiV pacing at a lower rate of 40
Experimental: Bi-V DDD-40 to RV DDD-40 to VVI-40; Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40	Device: VVI-40; Pacing mode set to VVI-40, RV only pacing; Device: RV DDD-40; ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.; Device: BiV DDD-40; ICD programmed to BiV pacing at a lower rate of 40
Experimental: RV DDD-40 to VVI-40 to Bi-V DDD-40; Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40	Device: VVI-40; Pacing mode set to VVI-40, RV only pacing; Device: RV DDD-40; ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.; Device: BiV DDD-40; ICD programmed to BiV pacing at a lower rate of 40
Experimental: RV DDD-40 to Bi-V DDD-40 to VVI-40; Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40	Device: VVI-40; Pacing mode set to VVI-40, RV only pacing; Device: RV DDD-40; ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.; Device: BiV DDD-40; ICD programmed to BiV pacing at a lower rate of 40

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The Primary Endpoint of the Trial Will be a Comparison of the Proportion of Patients in Each of the Three Treatment Groups Who Demonstrate Positive LV Remodeling, Defined as a Decrease in LV End Systolic Diameter of >5mm.	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Left Ventricular Ejection Fraction (LVEF)		6 months
Secondary Echocardiographic Endpoints	Comparisons of the derived velocity-time integral calculated on the aortic continuous wave Doppler-spectrogram, RV end-diastolic size, RV EF, mitral and tricuspid regurgitation severity, and estimated RV systolic pressure.	6 months
Arrhythmic Events	To determine if pacing mode impacts the frequency of ventricular arrhythmias, the incidence of ventricular tachyarrhythmia episodes on device interrogation will be compared between treatment group assignments. An episode will be considered ventricular arrhythmia if it lasts longer than 30 seconds or requires anti-tachycardia pacing or high voltage device therapy for termination.	6 months
Minnesota Quality of Life Questionnaire	This is a standardized method for assessing quality of life in patients with heart failure. It asks 21 questions and measures the impact HF has on a subject's life. Each question is rated 0-5. The total score for the 21 items can range from 0 to 105. Higher scores indicate more burden of disease on quality of life.	6 months
6-minute Walk Distance	6-minute walk distance was the distance that a participant could walk in 6 minutes.	6 months
NYHA Function Class	The New York Heart Association (NYHA) Functional Classification places patients in one of four categories based on how much they are limited during physical activity. Class I means there is no limitation of physical activity and Class IV means a person is unable to carry on any physical activity without discomfort/symptoms of heart failure at rest.	6 months
Left Ventricular End-diastolic Size		6 months

Collaborators and Investigators

• Sponsor: Duke University
• Collaborators: American Heart Association
• Investigators: Principal Investigator: Brett D Atwater, MD, Duke University

Study record dates

Study Major Dates

• Study Start: January 1, 2011
• Primary Completion (Actual): August 1, 2014
• Study Completion (Actual): August 1, 2014

Study Registration Dates

• First Submitted: July 22, 2010
• First Submitted That Met QC Criteria: July 22, 2010
• First Posted (Estimate): July 26, 2010

Study Record Updates

• Last Update Posted (Estimate): September 23, 2016
• Last Update Submitted That Met QC Criteria: August 1, 2016
• Last Verified: August 1, 2016

More Information

Terms related to this study

• Keywords: Heart Failure; Cardiac Resynchronization Therapy; Right Bundle-Branch Block
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Arrhythmias, Cardiac; Cardiac Conduction System Disease; Heart Failure; Bundle-Branch Block; Heart Block
• Other Study ID Numbers: Pro00025144; 10CRP3630033 (Other Grant/Funding Number: American Heart Association)